Sermorelin — Evidence & FDA Status
Sermorelin: previous FDA-approved status, current availability via compounding, evidence base and provider considerations.
Evidence-based answer
Sermorelin: previous FDA-approved status, current availability via compounding, evidence base and provider considerations.
Regulatory status: There is no currently marketed FDA-approved sermorelin product for anti-aging or body-composition treatment. Compounded sermorelin is an unapproved prescription product.
How it works
Sermorelin is an analog of growth-hormone-releasing hormone that can stimulate pituitary growth hormone secretion when the axis is functional.
Mechanism is context, not proof. A defensible claim requires human outcome data for the exact molecule, formulation, dose and population. Receptor activity alone cannot establish how much weight a patient will lose, whether an injury will heal or whether a compounded vial has the identity and potency of a trial product.
What the clinical evidence shows
Historical diagnostic and pediatric use does not establish benefits for anti-aging, athletic performance or routine adult weight management. Contemporary high-quality trials are limited.
| Study or evidence level | Population | Intervention | Main result | Interpretation |
|---|---|---|---|---|
| Evidence grade | Varies by molecule | Exact product and route required | See primary sources | Do not extrapolate animal or mechanism data to human outcomes |
Clinical-use framework
No FDA-approved anti-aging dose exists. Individualized compounded directions are not equivalent to an approved label.
A safe plan includes medical history, medication reconciliation, pregnancy screening where relevant, contraindication review, a written titration or administration schedule, missed-dose instructions, side-effect escalation and follow-up. Laboratory testing is individualized; a universal panel is not evidence-based for every patient, but clinicians may order testing based on symptoms, comorbidities and the medicine considered.
How to evaluate an online program
- Identify the legal entities. The marketing company, prescribing practice and dispensing pharmacy may be different organizations.
- Confirm the clinician. Look for a full name, credential, NPI where applicable and authority to practice in the patient’s state.
- Read the prescription label. Verify the exact drug, salt or base, concentration, directions, facility and beyond-use date.
- Normalize cost. Add medication, membership, visits, labs, supplies, shipping and dose surcharges.
- Match the evidence. Ask whether the offered dose and route were studied for the claimed outcome.
- Review continuity. Understand refills, cold-chain handling, replacement, pharmacy changes and cancellation.
Safety
Potential concerns include edema, joint symptoms, glucose effects, injection reactions and inappropriate stimulation in patients with active malignancy. Product quality depends on the dispensing facility.
This page is educational and does not replace diagnosis or individualized prescribing. Severe symptoms, suspected overdose or a serious allergic reaction require urgent in-person evaluation.
Frequently asked questions
Is sermorelin FDA approved?
There is no currently marketed FDA-approved sermorelin product for anti-aging or body-composition treatment. Compounded sermorelin is an unapproved prescription product.
What is the strongest evidence for sermorelin?
Historical diagnostic and pediatric use does not establish benefits for anti-aging, athletic performance or routine adult weight management. Contemporary high-quality trials are limited.
Can a compounded or microdose product claim the same trial result?
Not automatically. The trial result applies most directly to the studied product, dose, titration, population and duration. A different formulation, route or lower dose requires its own evidence.
What should be verified before treatment?
Verify the exact product, indication, prescriber, pharmacy, concentration, dose schedule, recurring cost, commitment, follow-up plan and urgent-care instructions.
Primary sources
- FDA human drug compounding Primary clinical or regulatory source
Provider marketing can document what is offered; it is not used as proof of safety or comparative effectiveness. Evidence was reviewed through July 12, 2026.